


ADVANCED HEART FAILURE SYMPOSIUM

SATURDAY
OCTOBER 19
MARRIOTT MARQUIS
WASHINGTON, DC



INOVA[®]

Heart and Vascular Institute

Approved for CME Credits: *AMA PRA Category 1 Credit™*
7 ABIM MOC Points
8.4 Nursing Contact Hours

Program Description

The *Inova Heart and Vascular Institute 2019 Advanced Heart Failure Symposium* will provide a review of best practices in the field of heart failure, including current guidelines, co-morbidities with a particular emphasis on diabetes, innovative and novel pharmacological and technological treatment options and health policy concerns. The role of mechanical support, the differences in the types of devices, possible complications, and the latest thinking on home monitoring, surgical approaches and transplantation will be presented and discussed in detail to help physicians and healthcare providers make better informed decisions regarding referral for transplant or mechanical cardiac support.

Through interactive lectures, case studies and panel discussions, world renowned experts will present the very latest research and clinical trial results with an emphasis on the application to day to day clinical practice.

The program will cover the following general topics:

- Guideline Directed Medical Therapy and Novel Approaches to Heart Failure Management
- Cutting Edge Device Therapy for Heart Failure
- Treatment Options for Advanced Heart Failure
- New insights on the Management of Amyloid, HOCM, and other interesting clinical cases

Target Audience

- Heart Failure specialists
- Cardiovascular clinicians
- Primary care physicians, hospitalists
- Fellows and residents in training
- Advanced practice nurses and other non-physician members of the cardiac care team

Educational Objectives

Upon completion of this course, participants should be able to:

- Understand and apply novel approaches and new pharmacological treatment options for the management of heart failure
- Utilize novel treatments for mitral regurgitation, comorbidities, and arrhythmias appropriately
- Delineate the best practices for when to refer advanced heart failure patients for evaluation for heart transplant or mechanical cardiac support

CME Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the Joint Providership of the The University of Massachusetts Medical School and Inova Heart and Vascular Institute. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The University of Massachusetts Medical School designates this live activity for a maximum of *7 AMA PRA Category 1 Credit(s)TM*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ABIM MOC

Earn up to 7 ABIM MOC Points.

Nursing Contact Hours

This live activity meets the requirements for up to 8.4 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04).



Endorsement

The 2019 IHVI Advanced Heart Failure Symposium is officially endorsed by the Heart Failure Society of America.

The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.



FRIDAY, OCTOBER 18, 2019

6:00 – 7:15 PM

WELCOME AND NETWORKING RECEPTION

SATURDAY, OCTOBER 19, 2019

7:30 – 8:00 AM

REGISTRATION, COFFEE, EXHIBITS

8:00 – 8:05 PM

OPENING REMARKS

Christopher M. O'Connor, MD

8:05 – 9:00 AM

Improving Outcomes in Cardiogenic Shock

Moderator: Shashank Desai, MD

8:05 – 8:15 AM

Why do We Care about Cardiogenic Shock?

Carolyn Rosner, RN

8:15 – 8:25 AM

What has been done to Treat Cardiogenic Shock?

Alexander Truesdell, MD

8:25 – 8:35 AM

How is Cardiogenic Shock Managed at IHVI and how has that Changed Outcomes

Behnam Tehrani, MD

8:35 – 9:00 AM

Panel Discussion

Carolyn Rosner, Shashank Sinha, Behnam Tehrani, Alex Truesdell

9:00 – 9:05 AM

Keynote Introduction

Christopher M. O'Connor, MD

9:05 – 9:50 AM

KEYNOTE LECTURE

SGLT2i for Heart Failure: An Update in a Rapidly Moving Field

Eugene Braunwald, MD

9:55 – 11:15 AM

DRUG THERAPY FOR HEART FAILURE

Moderators: Michael Bristow, MD, PhD; Mona Fiazat, PharmD

9:55 – 10:05 AM

The Current State of Heart Failure: How are We Doing?

Mariell Jessup, MD

10:05 – 10:15 AM

Current Management Strategies in HFpEF

Peter Carson, MD

10:15 – 10:25 AM

What's New in the AHA/ACC/HFSA Guidelines

Clyde Yancy, MD

10:25 – 10:35 AM

Managing Chronic HF

G. Michael Felker, MD

10:35 – 10:45 AM

Anticoagulation in the HF Patient

John Teerlink, MD

10:45 – 10:55 AM

Managing RV Failure and Pulmonary Hypertension

Mitchell Psozka, MD, PhD

10:55 – 11:15 AM

Panel Discussion

Peter Carson, G. Michael Felker, Mariell Jessup, Mitchell Psozka, John Teerlink, Clyde Yancy

11:15 - 11:35 AM

EXHIBIT AND NETWORKING BREAK, POSTERS

**SESSION 2:
DEVICES**

11:35 – 1:00 PM

CUTTING EDGE DEVICE THERAPY FOR HEART FAILURE

Moderators: *Peter Carson, MD; Melvin Echols, MD*

11:35 – 11:45 AM

Novel Device Therapies for HF

William Abraham, MD

11:45 – 11:55 PM

Hemodynamic Monitoring in the Modern Era

Lauren Cooper, MD

11:55 – 12:05 PM

Interventional Heart Failure

Wayne Batchelor, MD

12:05 – 12:15 PM

Mitral Regurgitation: Interpreting COAPT and MITRA-FR

JoAnn Lindenfeld, MD

12:15 – 12:25 PM

Device Considerations in Special Populations

Mariell Jessup, MD

12:25 – 12:35 PM

Managing HF Patients after ICD/CRT Implantation

Amrut Ambardekar, MD

12:35 – 1:00 PM

Panel Discussion

Amrut Ambardekar, Wayne Batchelor, Lauren Cooper, JoAnn Lindenfeld, Mariell Jessup, Patient

LUNCH

1:00 – 1:55 PM

LUNCH, EXHIBITS AND NETWORKING

1:20 – 1:45 PM

Poster Session

Moderators / Judges

Lauren Cooper, MD; Christopher deFilippi, MD; Mitchell Psotka, MD, PhD; Palak Shah, MD;

2:00 – 3:15 PM

SPECIAL POPULATIONS AND INTERESTING CASES

Moderators: *Christopher M. O'Connor, MD; Palak Shah, MD*

2:00 – 2:10 PM

Peripartum/Post-Partum Cardiomyopathy

JoAnn Lindenfeld, MD

2:10 – 2:20 PM

Cardio-Oncology

Bonnie Ky, MD

2:20 – 2:30 PM

Amyloid

Mathew Maurer, MD

2:30 – 2:40 PM

Heart Failure in Women

Kelly Epps, MD

2:40 – 2:50 PM

Heart Failure in the Elderly

Tariq Ahmad, MD

2:50 - 3:15 PM

Interesting Clinical Cases with Panel Discussion

Presenter: *Nasrien Ibrahim, MD*

Panelists:

Tariq Ahmad, Kelly Epps, Bonnie Ky, JoAnn Lindenfeld, Mathew Maurer

**SESSION 3:
SPECIAL POPULATIONS**

**SESSION 4:
ADVANCED HF**

3:15 - 3:30 PM	EXHIBIT AND NETWORKING BREAK, POSTERS
3:30 – 4:40 PM	CUTTING EDGE CONCEPTS IN ADVANCED HEART FAILURE Session Moderator: <i>Robert Cole, MD; Daniel Tang, MD</i>
3:30 – 3:40 PM	Impact of the New Allocation System <i>Joseph Rogers, MD</i>
3:40 – 3:50 PM	HF Referrals: Timing is Key <i>Shashank Desai, MD</i>
3:50 – 4:00 PM	End Stage Heart Failure: ECMO and Beyond <i>Robert Cole, MD</i>
4:00 – 4:10 PM	Management of LVAD patients for the Non-LVAD Specialist <i>Tariq Ahmad, MD</i>
4:10 – 4:20 PM	Cutting Edge Concepts in Surgical Options <i>Daniel Tang, MD</i>
4:20 – 4:40 PM	Panel Discussion <i>Tariq Ahmad, Lauren Cooper, Shashank Desai, Joseph Rogers, Palak Shah</i>
4:40– 4:55 PM	POSTER AWARDS, RAFFLE WINNERS, CLOSING REMARKS <i>Christopher M. O'Connor, MD</i>



Eugene Braunwald, MD
Keynote Speaker



Christopher O'Connor, MD
Course Director



Shashank Desai, MD
Co-Chair



Mona Fiuzat, PharmD
Co-Chair

FACULTY

William Abraham, MD, FACC, FAHA, FESC
Professor of Medicine, Physiology, and Cell Biology
Associate Dean for Clinical Research
Director, Clinical Trials Management Office
Deputy Director, Davis Heart and Lung
Research Institute
The Ohio State University

Tariq Ahmad, MD, MPH, FACC
Advanced Heart Failure and Transplant
Assistant Professor of Medicine
Yale New Haven Health System

Amrut V. Ambardekar, MD, FACC, FHFSA
Medical Director Cardiac Transplant Program
Director of Clinical Research
Division of Cardiology
University of Colorado

Wayne Batchelor, MD, MHS, FACC, FSCAI
Director of the Interventional Heart Program,
Inova Health System
Director of Interventional Heart Disease Research,
Education, and Innovation
Associate Director
Inova Heart and Vascular Institute

Eugene Braunwald, MD, MACC, FAHA, FESC
Distinguished Hersey Professor of Medicine
Harvard Medical School
Founding Chairman of the TIMI Study Group
Brigham and Women's Hospital

Michael Bristow, MD, PhD, FACC, FHFSA
Professor of Medicine (Cardiology)
Director of Pharmacogenomics
University of Colorado Division of Cardiology
President and CEO
ARCA Biopharma

Peter Carson, MD, FACC
Clinical Professor of Medicine Georgetown University
Director, Heart Failure Program
Washington DC VA Medical Center

Robert Cole, MD, FACC, FHFSA
Director, Heart Failure Section IHVI
Director, Inova Heart Failure Site Based Research
Inova Heart and Vascular Institute

Lauren Cooper, MD, MHS, FACC, FHFSA
Director of Heart Failure Disease Management Clinic
Associate Director of Heart Failure Research
Inova Heart and Vascular Institute

Christopher deFilippi, MD, FACC

Vice Chair of Academic Affairs,
Director of Cardiology Fellowship Program
Inova Heart and Vascular Institute

Shashank Desai, MD, FACC

Medical Director, Advanced Heart Failure and
Transplant Program, Inova Health System
Inova Heart and Vascular Institute

Melvin R. Echols, MD, FACC

Assistant Professor of Medicine
Department of Cardiology
Program Director, Cardiovascular Disease Fellowship
Camp Creek Cardiovascular Disease Clinic

Kelly Epps, MD, MSHP, FACC

Interventional Cardiology, Cardiovascular Disease
Inova Heart and Vascular Institute

G. Michael Felker, MD, FACC, FHFSa

Chief, Heart Failure Section
Director, Heart Failure Research, DCRI
Professor of Medicine
Duke University

Mona Fiuzat, PharmD, FACC, FHFSa, FHFA

Former Sr. Scientific Advisor to FDA Commissioner
Associate Professor of Medicine
Duke University

Nasrien E. Ibrahim, MD, FACC, FHFSa

Assistant Professor, Harvard Medical School
Advanced Heart Failure and Transplant Cardiologist,
Massachusetts General Hospital

Mariell Jessup, MD, FACC, FAHA, FHFA

Emeritus Professor of Medicine
University of Pennsylvania
Chief Science and Medical Officer
American Heart Association

Bonnie Ky, MD, MSCE, FACC

Associate Professor of Medicine
Perelman School of Medicine
University of Pennsylvania

JoAnn Lindenfeld, MD, FACC, FAHA, FHFSa

Director, Heart Failure and Transplant Program
Professor of Medicine
Vanderbilt University

Mathew Maurer, MD, FACC

Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center Director
Clinical Cardiovascular Research Laboratory for the Elderly
New York Presbyterian Hospital

Christopher O'Connor, MD, MACC, FESC, FHFSa

President
Inova Heart and Vascular Institute
Professor of Medicine
Duke University

Mitchell Psotka, MD, PhD

Advanced Heart Failure, Transplant, and Pulmonary
Hypertension
Associate Director Heart Failure Site Based Research
and Heart Failure Outreach Programs
Inova Heart and Vascular Institute

Joseph G. Rogers, MD, FACC, FHFSa

Professor of Medicine, Division of Cardiology
Chief Medical Officer
Duke University Health System

Carolyn Rosner, RN, MSN, NP-C

Director IHVI Programs

Palak Shah, MD, MS, FACC, FHFSa

Director, Cardiovascular Genomics Center
Director, Heart Failure Research
Inova Heart and Vascular Institute
Assistant Professor of Medicine
George Washington University

Shashank Sinha, MD, MSc, FACC

Advanced Heart Failure & Transplant
Director, Cardiac Intensive Care Unit
Inova Heart & Vascular Institute

Daniel Tang, MD, FACC, FACS

Chief, Cardiothoracic Transplantation
Inova Heart and Vascular Institute

John Teerlink, MD, FACC, FESC, FAHA, FHFSa

Director, Heart Failure Program and Clinical
Echocardiography Lab,
San Francisco VA Medical Center
Professor of Medicine,
University of California, San Francisco

Behnam Tehrani, MD, FACC, FSCAI

Director, Cardiac Catheterization Laboratory
Inova Heart and Vascular Institute

Alexander Truesdell, MD, FACC, FSCAI

Interventional Cardiologist
Inova Heart and Vascular Institute


Clyde Yancy, MD, MACC, FAHA, FHFSa

Vice Dean for Diversity and Inclusion
Chief of Cardiology, Department of Medicine
Northwestern Feinberg School of Medicine

LVEF Improvement Demonstrated in High-Risk Patients

Several PCI studies utilizing the Impella heart pump, including U.S. Impella Registry, PROTECT I, PROTECT II and the recent Burzotta publication have demonstrated improvement in LVEF^{1,4}

Multiple Studies Highlight Patient Benefits After Protected PCI



1. Maini et al. Catheter Cardiovasc Interv. 2012 Nov 1;80(5):717-25.
2. O'Neill et al. Circulation. 2012 Oct 2;126(14):1717-27.
3. Burzotta et al. Long-Term Outcomes of Extent of Revascularization in Complex High Risk Indicated Patients. JIC. 2019
4. Dixon et al. JACC Cardiovasc Interv. 2009 Feb;2(2):51-6.

All cardiovascular procedures have risk. Potential adverse events associated with the use of Impella include: acute renal dysfunction, aortic valve injury, bleeding, cardiogenic shock, stroke, hemolysis, limb ischemia, myocardial infarction, renal failure, thrombocytopenia, vascular injury and death.

To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.abiomed.com/important-safety-information

Impella
The Heart's Future



Creating a healthier future.

Every day, we challenge ourselves to help people suffering from cardiovascular diseases.

Building on a heritage of 120 years of innovation, we are committed to prevention and treatment.

Together, we are making a difference.



SURVIVAL NEVER LOOKED SO GOOD

THE WORLD'S SMALLEST CENTRIFUGAL VAD

with more than 18,000 implants worldwide and clinical evidence to prove its safety and effectiveness when used in a less-invasive thoracotomy approach.^{1,2}



References:

1. McGee E, Danter M, et al. Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. JHLT. 2019;38(4):344-351.
2. Medtronic data on file as of July 2019, and data extrapolated based on source data from: HVAD System Instructions for Use. HeartWare Inc., Framingham, MA, USA 07/18. HeartMate 3 Left Ventricular Assist System, Instructions for Use. Thoratec Corporation, Pleasanton, CA, USA 02/17.

Brief Statement: HeartWare™ HVAD™ System

Indications for Use

The HeartWare™ HVAD™ System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure, either as a Bridge to Cardiac Transplantation (BTT), myocardial recovery, or as Destination Therapy (DT) in patients for whom subsequent transplantation is not planned.

Contraindications

The HeartWare System is contraindicated in patients who cannot tolerate anticoagulation therapy.

Refer to the "Instructions for Use" for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions and potential adverse events prior to using this device.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

Medtronic

14400 NW 60th Ave
Miami Lakes, FL 33014
Tel: (305) 364-1402
Fax: (954) 874-1401

medtronic.com

UC202001492 EN © Medtronic 2019
Minneapolis, MN. All Rights Reserved.

Printed in the USA. 08/2019 HeartWare, HVAD, Medtronic
and Medtronic logo are trademarks of Medtronic.

Medtronic